Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma

Chan Yoon CheahDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Haleigh E. MistryDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Sergej KonoplevDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Nathan H. FowlerDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Correspondence[email protected]

Supplemental material

Supplementary Figure 1. NLPHL growth patterns present (according to Fan et al[2]). The letter denotes the histologic growth pattern in each case. CD20 immunohistochemical stain, 100x magnification.

Download TIFF Image (37.5 MB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma

ICMJE Uniform Disclosure Form for Potential Conflicts of Interest

ICMJE Uniform Disclosure Form for Potential Conflicts of Interest

ICMJE Uniform Disclosure Form for Potential Conflicts of Interest

ICMJE Uniform Disclosure Form for Potential Conflicts of Interest

Supplementary Figure 1. NLPHL growth patterns present (according to Fan et al[2]). The letter denotes the histologic growth pattern in each case. CD20 immunohistochemical stain, 100x magnification.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma

ICMJE Uniform Disclosure Form for Potential Conflicts of Interest

ICMJE Uniform Disclosure Form for Potential Conflicts of Interest

ICMJE Uniform Disclosure Form for Potential Conflicts of Interest

ICMJE Uniform Disclosure Form for Potential Conflicts of Interest

Supplementary Figure 1. NLPHL growth patterns present (according to Fan et al[2]). The letter denotes the histologic growth pattern in each case. CD20 immunohistochemical stain, 100x magnification.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date